# Lipo-prostaglandin E1 Improves Renal Hypoxia Evaluated by BOLD-MRI in Patients With Diabetic Nephropathy

> **NCT02628106** · PHASE4 · COMPLETED · sponsor: **West China Hospital** · enrollment: 21 (actual)

## Conditions studied

- Diabetic Nephropathy

## Interventions

- **DRUG:** Lipo-PGE1

## Key facts

- **NCT ID:** NCT02628106
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12
- **Primary completion:** 2016-01
- **Final completion:** 2016-02
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2016-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02628106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02628106, "Lipo-prostaglandin E1 Improves Renal Hypoxia Evaluated by BOLD-MRI in Patients With Diabetic Nephropathy". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02628106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*